Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
What's in Store for J&J's (JNJ) Segments & Pipeline in 2022?
01:20pm, Friday, 18'th Mar 2022 Zacks Investment Research
J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.
Wall Street Breakfast: Economically Assured Destruction
11:31am, Friday, 18'th Mar 2022 Seeking Alpha
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
09:45pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Moderna (MRNA) closed at $168.26 in the latest trading session, marking a -0.65% move from the prior day.
Why Moderna Stock Is Soaring This Week
09:15pm, Thursday, 17'th Mar 2022 The Motley Fool
A resurgence in COVID-19 cases in China and Europe is the key driver behind Moderna's rebound.
Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?
01:55pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.
Alnylam files patent infringement lawsuits against Pfizer, Moderna By Reuters
11:56am, Thursday, 17'th Mar 2022 Investing.com
Alnylam files patent infringement lawsuits against Pfizer, Moderna
Pfizer, Moderna set to make $51b in COVID-19 vaccine sales
03:53am, Thursday, 17'th Mar 2022 The Guardian Nigeria
•Non-profit company to produce generic insulin that will be sold for $30 per vial as discussions of price-caps for lifesaving drug is sparked after State of the Union address Pfizer and Moderna, manufacturers of the two most popular used vaccines in the United States and much of the rest of the world, are expecting to […] The post Pfizer, Moderna set to make $51b in COVID-19 vaccine sales appeared first on The Guardian Nigeria News - Nigeria and World News .
Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More
04:32pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Here''s Why Moderna Shares Are Rising
02:46pm, Wednesday, 16'th Mar 2022 Benzinga
Moderna Inc (NASDAQ: MRNA ) shares are trading higher by 7.0% … Full story available on Benzinga.com
Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults
12:32pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.
Moderna’s profits show why Big Pharma can’t meet our health needs
09:20am, Wednesday, 16'th Mar 2022 Al Jazeera
According to the company''s own accounts, Moderna brought in $13bn in pre-tax profits in 2021.
Japan plans to acquire 145M doses of Moderna, Pfizer/BioNTech COVID vaccines - Reuters
08:58am, Wednesday, 16'th Mar 2022 Seeking Alpha
Japan intends to acquire 145M doses of Moderna (MRNA), and Pfizer (PFE) and BioNTech''s (BNTX) COVID-19 vaccines, Reuters reported citing Kyodo news agency which cited a…
Moderna''s (MRNA) Management Presents at Barclays Global Healthcare Conference (Transcript)
11:19pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Is Moderna Stock a Buy Right Now? This Is What You Need to Know
09:06pm, Tuesday, 15'th Mar 2022 TipRanksAs Covid has shown us time and again over the past couple of years, the coronavirus will not be rid of easily. Following Russia’s invasion of Ukraine, it seemed to<…
China's COVID-19 Lockdown Brings Back Focus on Healthcare ETFs
09:00pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
Let's take a look at some healthcare ETFs that are regaining popularity among investors as COVID-19 cases rise in China.
